Kevin Kalinsky, MD, MS, on the RxPONDER Trial Methods

Video

In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.

In the phase 3 RxPONDER trial (NCT01272037), investigators evaluated the use of endocrine therapy versus chemotherapy followed by endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer with a recurrence score between 0 and 25.

Patients with HR–positive, HER2-negative, lymph node–positive breast cancer have an increased risk of recurrence and are typically treated with chemotherapy. Therefore, to prevent potential overtreatment or undertreatment, the 21-gene Oncotype Dx Recurrence Score is used to identify which patients with these disease characteristics can omit chemotherapy.

Investigators launched the RxPONDER trial, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy. CancerNetwork® spoke with Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine as well as director of the Glenn Family Breast Center and director of breast medical oncology at Winship Cancer Institute of Emory University, about the trial and its methods.

Transcription:

We prespecified the analysis to look at whether there was a difference in effect for those patients who are postmenopausal versus pre[menopausal]. And there was a separate landmark study called the TAILORx trial [NCT00310180] for patients who had [lymph] node–negative breast cancer, but the same subtype, hormone receptor–positive and -negative [breast cancer]. And they saw in an exploratory analysis that there was a difference depending upon age. I think that when we look at menopausal status, I’m not sure if we were surprised. I think we’re surprised at how different the populations work.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content